Quantity of suitable patients: CDEC talked about the uncertainty in the quantity of individuals with moderately severe to intense hemophilia B in Canada eligible for etranacogene dezaparvovec. Medical specialists consulted by CADTH indicated that some patients that are categorised as having mild or reasonable condition may have a significant bleeding https://soichiroo912dcc2.wikinarration.com/user